Evidence map›Paper›PMID 36790955›Full record

ArticleMolecular cancer research : MCR2023

Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling.

Dandan Li, Anne M Miermont, Rushikesh Sable, Humair S Quadri, Lesley A Mathews Griner, Scott E Martin, Taivan Odzorig, Soumita De, Marc Ferrer, Astin S Powers and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Dandan Li *Thoracic and GI Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.ORCID 0000-0001-9139-3118
Anne M Miermont *Thoracic and GI Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.ORCID 0000-0001-8366-5304
Rushikesh SableRare Tumor Initiative, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.ORCID 0000-0002-6128-2190
Humair S QuadriThoracic and GI Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.ORCID 0000-0003-1708-5269
Lesley A Mathews GrinerDivision of Pre-Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland.ORCID 0000-0001-9847-1107
Scott E MartinTrans-NIH RNAi Facility (TNRF), National Center for Advancing Translational Sciences, Rockville, Maryland.ORCID 0000-0001-5685-9787
Taivan OdzorigRare Tumor Initiative, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.ORCID 0000-0002-0877-2692
Soumita DeRare Tumor Initiative, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.ORCID 0000-0003-3247-0317
Marc FerrerDivision of Pre-Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland.ORCID 0000-0003-4569-9137
Astin S PowersExperimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.ORCID 0000-0002-6514-2670
Stephen M HewittExperimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.ORCID 0000-0001-8283-1788
Udo RudloffThoracic and GI Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.ORCID 0000-0003-2137-9040
National Cancer Institute · USNational Center for Advancing Translational Sciences · US

Funding

Preclinical drug development in pancreatic cancerZIABC011267 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI RUDLOFF, UDO · 2010 to 2025
$23.9M
Experimental Pathology Laboratory (EPL)ZICBC011638 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HEWITT, STEPHEN · 2015 to 2025
$16.6M
Trans-NIH RNAi Facility (TNRF)ZICTR000041 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI CHENG, KEN · 2015 to 2025
$9.4M
Intramural NIH HHS Z99 CA999999Intramural NIH HHS ZIA BC011267
6 · The paper itself

Abstract

Combinatorial molecular therapy in pancreatic ductal adenocarcinoma (PDAC) has yielded largely disappointing results in clinical testing to-date as a multitude of adaptive resistance mechanisms is making selection of patients via molecular markers that capture essential, intersecting signaling routes challenging. Here, we report the scaffolding protein connector enhancer of kinase suppressor of Ras 1 (CNKSR1) as mediator of resistance to MAPK (MEK) inhibition. MEK inhibition in CNKSR1high cancer cells induces translocation of CNKSR1 to the plasma membrane where the scaffolding protein interacts with and stabilizes the phosphorylated form of AKT. CNKSR1-mediated AKT activation following MEK inhibition was associated with increased cellular p-PRAS40 levels and reduced nuclear translocation and cellular levels of FoxO1, a negative regulator of AKT signaling. In clinical PDAC specimens, high cytoplasmatic CNKSR1 levels correlated with increased cellular phospho-AKT and mTOR levels. Pharmacological co-blockade of AKT and MEK ranked top in induced synergies with MEK inhibition in CNKSR1high pancreas cancer cells among other inhibitor combinations targeting known CNKSR1 signaling. In vivo, CNKSR1high pancreatic tumors treated with AKT and MEK inhibitors showed improved outcome in the combination arm compared with single-agent treatment, an effect not observed in CNKSR1low models.Our results identify CNKSR1 as regulator of adaptive resistance to MEK inhibition by promoting crosstalk to AKT signaling via a scaffolding function for the phosphorylated form of AKT. CNSKR1 expression might be a possible molecular marker to enrich patients for future AKT-MEK inhibitor precision medicine studies. IMPLICATIONS: The CNKSR1 scaffold, identified within an RNAi screen as a novel mediator of resistance to MEK inhibition in pancreas cancer, connects the MAPK pathway and AKT signaling and may be adopted as a biomarker to select patients for combined MEK AKT blockade.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsCell Line, TumorHumansIntracellular Signaling Peptides and ProteinsMitogen-Activated Protein Kinase KinasesProtein Kinase InhibitorsProtein KinasesProto-Oncogene Proteins c-aktSignal TransductionCNKSR1 protein, humanIntracellular Signaling Peptides and ProteinsKSR-1 protein kinaseMitogen-Activated Protein Kinase KinasesProtein Kinase InhibitorsProtein KinasesProto-Oncogene Proteins c-akt

Identifiers

PMID36790955
PMCPMC10068447
OpenAlexW4320855933

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.